Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
March 28, 2026Kidney International ReportsOpen Access

Wcn26-2145 Impact of Histology on Efficacy of Sparsentan Therapy in Iga Nephropathy: Central Biopsy Review of Patients in the Protect Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlex MercerBHBruce HendrySMStephanie Moody

Discussion

Loading...

Member takes

Overview

Case highlights efficacy of telitacicept in kidney and neuromuscular conditions, suggesting dual benefits.

Key Points

  • This research investigates how different histological types affect the efficacy of sparsentan therapy in IgA nephropathy.
  • Conducted a central biopsy review of patients enrolled in the PROTECT trial.
  • Analyzed the histological variations among subjects receiving sparsentan therapy.
  • Assessed the impact of these variations on treatment outcomes.
  • Telitacicept showed potential benefits in managing renal autoimmunity.
  • The therapy demonstrated efficacy in addressing antibody-mediated dysfunctions.
  • Findings indicate a need for personalized treatment approaches based on histology.

Cite This Study

Mercer et al. (2026) studied this question.

synapsesocial.com/papers/69c770c08bbfbc51511e0b36https://doi.org/10.1016/j.ekir.2026.104302
View Full Paper
Ask AI
Bookmark
Share